Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to resiniferatoxin for pain associated with knee osteoarthritis (OA). The investigational, non-opioid medicine is currently in Phase III clinical development.
Knee OA affects more than 360 million people worldwide. Patients often experience severe pain, and many are impacted in their daily activities. If approved, resiniferatoxin could become a meaningful treatment option providing long-lasting pain relief and functional improvement of the affected joint.
Learn more about our asset and how it may address one of the most common and severe symptoms in knee OA
Download PR FDA Breakthrough Therapy Designation for Grünenthal’s resiniferatoxin
Janneke van der Kamp starts as the new Chief Commercial Officer (CCO) of Grünenthal on March first 2023. She succeeds Mark Fladrich, who retired on February 28, 2023. Janneke van der Kamp joins Grünenthal’s executive board and is responsible for the entire Global Commercial Organisation.
Grünenthal relies on solar power for its corporate headquarters
Our Aachen R&D and production site is soon home to the region's largest solar power plant. With over 4.000 solar panels, we will generate enough energy to power 500 households. Our goal is to reach net zero emissions by 2030, and this solar power plant will play a key role in reducing up to 366 tonnes of CO2 annually.
Learn more about our initiatives to reduce our environmental footprintGrünenthal announces Joint Venture Collaboration with Kyowa Kirin International for established medicines portfolio with sales of ~€200 million.
The transaction combines Grünenthals unrivalled expertise in pain management with Kyowa Kirin’s portfolio of valuable medicines anchored in pain management. Grünenthal intends to acquire the full portfolio at the beginning of 2026.
Grünenthal and Kyowa Kirin International announce Joint Venture Collaboration for established medicines portfolioGrünenthal announced that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX).
RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile.
Grünenthal starts global clinical Phase III programme for resiniferatoxin (RTX)
Working at Grünenthal means experiencing the impact you can have on the results we achieve and the lives of the patients we serve.
Join forces.
Make an impact.
Innovate for a world free of pain.
